.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: RE34712

« Back to Dashboard

Claims for Patent: RE34712

Title: Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof
Abstract:The two enantiomers of the anti-depressant drug of the formula I ##STR1## are disclosed. Methods for resolving intermediates and their .[.steroselective.]. .Iadd.stereoselective .Iaddend.conversion to a corresponding .[.enatiomer.]. .Iadd.enantiomer .Iaddend.of I are also disclosed.
Inventor(s): Boegesoe; Klaus P. (Horsholm, DK), Perregaard; Jens K. (J gerspris, DK)
Assignee: H. Lundbeck A/S (Copenhagen-Valby, DK)
Application Number:08/122,009
Patent Claims: 1. A compound selected from substantially pure (+)-1-(3-Dimethylaminopropyl)-1-(4'- fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile and non-toxic acid addition salts thereof.

2. A compound of claim 1 being .Iadd.the .Iaddend.pamoic acid salt of substantially pure (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran -5-carbonitrile.

3. A pharmaceutical composition in unit dosage form comprising a pharmaceutically acceptable diluent or adjuvant and, as an active ingredient, a compound as defined in claim 1.

4. A pharmaceutical composition in unit dosage form comprising a pharmaceutically acceptable diluent or adjuvant and, as an active ingredient, the compound of claim 2.

5. A pharmaceutical composition in unit dosage form, according to claim 3, wherein the active ingredient is present in an amount from 0.1 to 100 milligram per unit dose.

6. A pharmaceutical composition in unit dosage form, according to claim 4, wherein the active ingredient is present in an amount from 0.1 to 100 milligram per unit dose.

7. A method for the alleviation of depression in a living animal body subject thereto which comprises the step of administering to the living animal body an amount of a compound of claim 1 which is effective for said purpose.

8. A method for the alleviation of depression in a living animal body subject thereto which comprises the step of administering to the living animal body an amount of a compound of claim 2 which is effective for said purpose.

9. Method of claim .[.10.]. .Iadd.7 .Iaddend.wherein the compound is administered in the form of a pharmaceutical composition thereof.

10. Method of claim 8 wherein the compound is administered in the form of a pharmaceutical composition thereof.

11. A method for the preparation of a compound as defined in claim 1, which comprises, converting substantially, pure .[.(+)-4-(4-dimethylamino)-1-(4'-fluorophenyl)-1-(hydroxybutyl)-3-(hydroxy methyl)-benzonitrile.]. .Iadd.(-)-4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(h ydroxymethyl)-benzonitrile .Iaddend.or a .[.monomester.]. .Iadd.monoester .Iaddend.thereof in a stereoselective way to substantially pure (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroisobenzofuran -5-carbonitrile which is isolated as such or as a non-toxic acid addition salt thereof.

12. A compound of the formula .Iadd.(31)-Enantiomer of the compound 4-[4-(dimethylamino)-1-(4'-fluorophenyl)-1-hydroxy-1-butyl]-3-(hydroxymeth yl)-benzonitrile or an ester of said (-)enantiomer, which has the formula .Iaddend. ##STR6## wherein R is hydrogen or represents a group completing a labile ester.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc